Tempel G, von Hundelshausen B, Reeker W
Klinikum Rechts der Isar, Department of Anesthesiology, Munich, Germany.
Intensive Care Med. 1996 Oct;22(10):1043-7. doi: 10.1007/BF01699225.
To determine whether dipyrone has an opiate-sparing effect in post-operative pain therapy compared with placebo during patient-controlled morphine therapy (PCA) and to compare the effects on analgesia and respiratory and coagulation parameters.
Randomized, observer-blind, parallel-group, placebo-controlled study.
Surgical intensive care unit of a university hospital.
106 adult patients who were to undergo abdominal or urological surgery under 90-min standardized inhalational anaesthesia were entered and 103 were included in the efficacy analysis (53 on dipyrone, 50 on placebo).
Preprogrammed PCA (0.03 mg morphine/kg per bolus) with either dipyrone (initially 2.0 g i.v. and 1.0 g/2 ml i.v. at 4, 8 and 16 h) or placebo (saline).
Cumulative morphine consumption was calculated automatically during PCA. Pain intensity and pain relief and the investigator's global assessments of efficacy and tolerability were recorded on five-point verbal rating scales. Vital signs, standard laboratory parameters, respiratory rate, partial pressure of carbon dioxide (PCO2) and of oxygen, partial thromboplastin time (PTT) and Quick values were recorded. Total consumption of opiates in the dipyrone group (median 31.6 mg) was significantly less (p = 0.00015) than in the placebo group (median 50.3 mg), while pain relief (area under the curve) AUC was the same for both PCA+dipyrone (median 4.1) and PCA+placebo (median 3.9). Global assessment of efficacy was good to excellent in more than 90% of cases in both groups. Vital signs, respiratory rate, PCO2, PTT and Quick did not differ between groups. Adverse events were mainly nausea and/or vomiting (dipyrone, n = 4; placebo, n = 1); 1 patient in the placebo group had bradycardia. Three serious adverse events were unrelated to study medication. In 1 patient, the PCA programme malfunctioned and had to be changed.
Concomitant administration of dipyrone with on-demand morphine (PCA) reduces opiate consumption while maintaining post-operative pain relief with a low incidence of side-effects.
确定在患者自控吗啡治疗(PCA)期间,与安慰剂相比,安乃近在术后疼痛治疗中是否具有节省阿片类药物的作用,并比较其对镇痛、呼吸和凝血参数的影响。
随机、观察者盲法、平行组、安慰剂对照研究。
大学医院的外科重症监护病房。
106例成年患者计划在90分钟标准化吸入麻醉下接受腹部或泌尿外科手术,103例纳入疗效分析(53例使用安乃近,50例使用安慰剂)。
预编程PCA(每推注0.03mg吗啡/kg),同时使用安乃近(初始静脉注射2.0g,4、8和16小时时静脉注射1.0g/2ml)或安慰剂(生理盐水)。
PCA期间自动计算吗啡累积消耗量。疼痛强度和疼痛缓解情况以及研究者对疗效和耐受性的总体评估采用五点口头评定量表记录。记录生命体征、标准实验室参数、呼吸频率、二氧化碳分压(PCO2)、氧分压、部分凝血活酶时间(PTT)和Quick值。安乃近组阿片类药物总消耗量(中位数31.6mg)显著低于安慰剂组(中位数50.3mg,p = 0.00015),而PCA + 安乃近组(中位数4.1)和PCA + 安慰剂组(中位数3.9)的疼痛缓解(曲线下面积)AUC相同。两组超过90%的病例对疗效的总体评估为良好至优秀。两组间生命体征、呼吸频率、PCO2、PTT和Quick值无差异。不良事件主要为恶心和/或呕吐(安乃近组,n = 4;安慰剂组,n = 1);安慰剂组1例患者出现心动过缓。3例严重不良事件与研究用药无关。1例患者PCA程序出现故障,不得不更换。
安乃近与按需使用吗啡(PCA)联合使用可减少阿片类药物的消耗,同时维持术后疼痛缓解,且副作用发生率较低。